Andy joins us from Purespring Therapeutics, a VC-backed biotech developing gene therapies to treat chronic kidney diseases. He also supports Forcefield Therapeutics, a seed-stage biotech from the same VC portfolio that is developing cardio-protectant proteins. Prior to Purespring Andy was at Imperial College, a research-led STEM university building a new Innovation campus here at White City.